Source: Eur Respir Monogr 2018; 81: 312-330
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Eva Polverino, Javier Perez-Miranda. Antibiotic management and resistance. Eur Respir Monogr 2018; 81: 312-330

Member's Comments

No comment yet.

Related content which might interest you: Antibiotic stewardship Source: Annual Congress 2012 - Infection control of respiratory pathogens Year: 2012 Antibiotic resistance and clinical outcomes: the CAPNETZ experience Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Antibiotic stewardship in the community Source: Eur Respir Monogr 2017; 75: 111-126 Year: 2017 Antibiotic resistance in pulmonary infections: mechanisms and epidemiology Source: Eur Respir Monogr 2017; 75: 21-43 Year: 2017 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Prescribing and guidelines: both must improve to combat antimicrobial resistance Source: Eur Respir J 2012; 39: 1050 Year: 2012 Prescribing and guidelines: both must improve to combat antimicrobial resistance Source: Eur Respir J 2011; 37: 9-11 Year: 2011 Impact of antibiotic consumption in the evolution of respiratory pseudomonas antibiotic resistance Source: Eur Respir J 2006; 28: Suppl. 50, 787s Year: 2006 Antibiotic stewardship in respiratory infections Source: International Congress 2016 – Respiratory infections in high-income countries: old challenges and new threats Year: 2016 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Antibiotic stewardship in the hospital setting Source: Eur Respir Monogr 2017; 75: 127-149 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Epidemiological impact of antibiotic use/misuse in the community Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=165 Year: 2004 Multidrug resistant tuberculosis: clinical aspects and management Source: Eur Respir J 2001; 18: Suppl. 33, 235s Year: 2001 Antibiotic treatment considerations beyond guidelines Source: International Congress 2017 – Management of Hospital-Acquired Pneumonia (HAP)/Ventilator-associated pneumonia (VAP) Year: 2017